Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

18.73 +0.35 (+1.89%)
Streaming Delayed Price Updated: 10:00 AM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19% ↗
The companies are both working on treatments for a rare skin disease. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
News headline image
Expert Ratings for MoonLake ↗
 
Via Benzinga
News headline image
10 Analysts Have This to Say About MoonLake ↗
 
Via Benzinga
News headline image
Analyst Expectations for MoonLake's Future ↗
 
Via Benzinga
News headline image
Where MoonLake Stands With Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts ↗
Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023 ↗
 
Via Benzinga
News headline image
Why MoonLake Immunotherapeutics Stock Skyrocketed This Week ↗
Positive mid-stage results fueled a spike in the biotech's shares this week. 
Via The Motley Fool
News headline image
The 7 Most Promising Momentum Stocks to Own Now ↗
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility. 
Via InvestorPlace
News headline image
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
News headline image
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
News headline image
10 Short Squeeze Stocks To Watch: Baosheng Media, Toro Corp, Getty Images And More ↗
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
News headline image
Price Target For MoonLake Doubled: Analyst Says Lead Program Has 'Best-In-Class Profile' ↗
HC Wainwright has increased the price target for MoonLake Immunotherapeutics (NASDAQ: MLTX) from $37 to $75  
Via Benzinga
News headline image
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022 ↗
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for... 
Via Benzinga
News headline image
10 Short Squeeze Stocks To Watch: Asset Entities, Lightning eMotors, Bullfrog AI, Carvana And More ↗
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
News headline image
$40M Bet On MoonLake Immunotherapeutics? Check Out These 3 Stocks Insiders Are Buying ↗
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
10 Short Squeeze Stocks To Watch: A Leader That Moved Up 392 Positions, Intuitive Machines, Toro And More ↗
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
News headline image
MarketBeat Week in Review – 6/26 - 6/30
Markets headed into a holiday week cheering a lower-than-expected key inflation reading, but investors should expect volatility in a short trading week. 
Via MarketBeat
Topics Economy
News headline image
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review ↗
Major indexes rebounded strongly and many stocks flashed buy signals. 
Via Investor's Business Daily
News headline image
MoonLake Immunotherapeutics Makes a Moonshot on Trials
Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results. 
Via MarketBeat
News headline image
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
News headline image
Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today ↗
The heavily bullish sentiment on the company only grew on the second trading day of the week. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
MoonLake Immunotherapeutics, Applied Digital And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.